Localization of laminin subunits in the central nervous system in Fukuyama congenital muscular dystrophy: an immunohistochemical investigation.
We have undertaken an immunohistochemical study of laminin subunits in the central nervous system (CNS) of fetuses and patients with Fukuyama congenital muscular dystrophy (FCMD) and of controls including five fetuses. Immunoreaction product deposits with antibodies to laminin alpha 1, alpha 2, beta 1 and gamma 1, and beta-dystroglycan were detected on the surface and vessels of the CNS of controls. No staining with anti-alpha-sarcoglycan antibody was detected in the CNS. Neurons and glia did not react with any of the antibodies used. In utero expression of laminin subunits and beta-dystroglycan seemed to be lower in the cerebrum than in the spinal cord. Moreover, immunostaining for laminin alpha 2 and beta 1 tended to be weak on the fetal spinal cord surface. Expression of laminin subunits and dystrophin-associated proteins in the CNS may be modulated during development, as in the skeletal muscle. The distribution of immunoreaction product deposits was basically the same in FCMD and controls, although laminin alpha 2 and beta-dystroglycan expression appeared to be decreased in the CNS of the FCMD cases. Defects of the pial-glial barrier of the fetal brain surface have been considered the main cause of micropolygyria in FCMD, and these observations suggest that the co-localization and secondary loss of these proteins in association with the unknown product(s) of the FCMD gene might be involved in the CNS lesions of this disorder.
Yamamoto
T
T
Department of Pathology, Tokyo Women's Medical College, Japan.
Shibata
N
N
Kanazawa
M
M
Kobayashi
M
M
Komori
T
T
Ikeya
K
K
Kondo
E
E
Saito
K
K
Osawa
M
M
D000328:Adult; D000368:Aged; D002490:Central Nervous System / Q000737:chemistry* / Q000196:embryology / Q000473:pathology; D003094:Collagen / Q000032:analysis; D003598:Cytoskeletal Proteins / Q000032:analysis / Q000378:metabolism; D049030:Dystroglycans; D005260:Female; D005333:Fetus / Q000002:abnormalities / Q000737:chemistry / Q000473:pathology; D006801:Humans; D007120:Immunochemistry; D007797:Laminin / Q000032:analysis* / Q000378:metabolism; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis / Q000378:metabolism; D009136:Muscular Dystrophies / Q000151:congenital / Q000378:metabolism*; D011247:Pregnancy; D049031:Sarcoglycans; D013194:Staining and Labeling
D003598:Cytoskeletal Proteins; C483081:DAG1 protein, human; D007797:Laminin; D008562:Membrane Glycoproteins; D049031:Sarcoglycans; C102645:laminin alpha 2; C089141:laminin gamma 1; D049030:Dystroglycans; C084098:laminin A; D003094:Collagen